Custom Search
News
Friday 01 February 2008
Aurobindo gets approval for Sumatriptan Succinate tabs
Aurobindo Pharma Limited is pleased to announce that the company has received tentative approval from the US Food & Drug Administration to manufacture and market Sumatriptan Succinate Tablets 25mg, 50mg and 100mg.
Sumatriptan Succinate Tablets are the generic equivalent of GlaxoSmithKline's Imitrex® Tablets, which are indicated for the treatment of acute migraine headaches.
Annual sales of Sumatriptan Succinate Tablets 25mg, 50mg and 100m. in the US were approximately US$ 950 million for the twelve months ending MAT/3/2007 according to IMS Health data.
This is Aurobindo’s 63rd ANDA approval from the USFDA.